MetaVia Inc.

What they do

MetaVia is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. Its lead program is DA-1726, a dual GLP-1/glucagon receptor agonist in a Phase 1 Part 3 study in obese, otherwise healthy adults. It is also developing vanoglipel (DA-1241), a GPR119 agonist, as a potential combination therapy for MASH and type 2 diabetes. The company has no approved products and generates no revenue.

Revenue drivers

• DA-1726 — Lead clinical-stage candidate, a dual GLP-1/glucagon receptor agonist; no revenue today. Second-quarter 2026 direct R&D costs for DA-1726 were $2.7 million, the largest single R&D line.
• Vanoglipel (DA-1241) — GPR119 agonist being developed as a combination backbone in MASH and type 2 diabetes; no revenue today. Second-quarter 2026 direct R&D costs were $0.2 million.
• Other R&D — Minor early-stage spending of $40 thousand in the second quarter of 2026; no revenue.

Recent performance

For the second quarter ended June 30, 2026, MetaVia reported a net loss of $5.3 million, or $0.90 per basic and diluted share, compared with a net loss of $4.0 million, or $2.87 per share, in the prior-year quarter. Total operating expenses rose 25.2% to $5.4 million, driven by a 49.9% increase in R&D to $3.5 million, mainly for the DA-1726 Phase 1 trial, partly offset by a 3.7% decline in G&A to $1.9 million. For the first six months of 2026, the net loss was $9.1 million versus $7.7 million a year earlier, with R&D of $5.6 million and G&A of $3.8 million.

Strategy

MetaVia is advancing DA-1726 through its ongoing Phase 1 Part 3 study, expecting a 16-week topline data readout in the fourth quarter of 2026. It also plans an End-of-Phase 2 meeting with the FDA in the second half of 2026 for the vanoglipel combination therapy in MASH. Because it has no revenue, the company expects to fund operations through equity offerings, debt financing, collaborations or licensing arrangements. It believes existing cash plus proceeds from its January 2026 public offering will fund operations into the fourth quarter of 2026, and management has stated there is substantial doubt about its ability to continue as a going concern.

Risks

• Going concern — MetaVia concluded there is substantial doubt about its ability to continue as a going concern within twelve months, and its auditor included a similar going-concern opinion in the 2025 Form 10-K.
• No product revenue — The company does not generate revenue and depends on external capital to fund development, so failure to raise funds on acceptable terms could force it to delay, limit or terminate operations.
• Clinical trial risk — Lead candidate DA-1726 is still in Phase 1 testing, and its 16-week Part 3 data expected in the fourth quarter of 2026 may not support further development.
• Dilution — Existing outstanding warrants to purchase 722,644 shares as of December 31, 2025, and future equity or convertible debt financings, could materially dilute current stockholders.

Outlook

Management expects a 16-week topline data readout from the Phase 1 Part 3 study of DA-1726 in the fourth quarter of 2026, covering 48 mg one-step and 64 mg two-step titration. It is working to schedule an End-of-Phase 2 FDA meeting in the second half of 2026 for the vanoglipel combination therapy. The company states its existing cash plus January 2026 offering proceeds should fund operations into the fourth quarter of 2026, beyond which it will need additional capital.